AbCellera Biologics Inc. (ABCL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.
Analysis Summary
AbCellera Biologics Inc. reported revenue of $75.1M in the most recent fiscal year, growing at a 5-year CAGR of -20.3%.
Trailing-twelve-month margins: gross margin 75.0%, operating margin -340.3%, net margin -248.8%.
At the current price of $11.42, ABCL has negative trailing earnings (P/E not meaningful) and an ROE of -17.49%. Market capitalisation stands at $3.5B.
Balance sheet quality for ABCL: current ratio of 11.3, net cash position of $390.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $11.42 |
| Market Cap | $3.5B |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 3.98 |
| EV / EBITDA | -22.33 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -17.49% |
| Return on Invested Capital | -14.95% |
| Return on Assets | -12.59% |
| Gross Margin | 74.95% |
| Operating Margin | -340.25% |
| Net Margin | -248.83% |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 12.77 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.66 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.5B | 3.98 | -17.5% | |
| SYRE | Spyre Therapeutics, Inc. | $7.9B | 7.02 | ||
| CLDX | Celldex Therapeutics, Inc. | $2.6B | 4.25 | -52.4% | |
| IMNM | Immunome, Inc. | $2.3B | 5.06 | -50.6% | |
| PHVS | Pharvaris N.V. | $2.7B | 7.35 | -61.2% | |
| NUVB | Nuvation Bio Inc. | $2.0B | 7.68 | -66.9% |
Price Performance
| 1 month | +2.88% |
| 3 months | +106.87% |
| Year-to-date | +234.50% |
| 1 year | +150.33% |
| 3 years | +123.00% |
| 5 years | -43.81% |
52-Week Range
| 52-week High | $12.58 |
| 52-week Low | $2.75 |
| Avg Volume (90d) | 7.5M |
Related companies: BHVN · CLDX · IMNM · JANX · NUVB · PHVS · SION
Explore sector: Healthcare · Biotechnology
More sections of ABCL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks